Literature DB >> 24128936

PharmGKB summary: venlafaxine pathway.

Katrin Sangkuhl1, Julia C Stingl, Miia Turpeinen, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24128936      PMCID： PMC4098656          DOI： 10.1097/FPC.0000000000000003

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  57 in total

1.  Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.

Authors:  Alice I Nichols; Kristen Focht; Qin Jiang; Sheldon H Preskorn; Cecelia P Kane
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?

Authors:  Matthew Macaluso; Sheldon H Preskorn
Journal:  J Clin Psychopharmacol       Date:  2011-04       Impact factor: 3.153

3.  Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.

Authors:  Corbin J Bachmeier; David Beaulieu-Abdelahad; Nowell J Ganey; Michael J Mullan; Gary M Levin
Journal:  Biopharm Drug Dispos       Date:  2011-03-28       Impact factor: 1.627

4.  O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.

Authors:  S M Fogelman; J Schmider; K Venkatakrishnan; L L von Moltke; J S Harmatz; R I Shader; D J Greenblatt
Journal:  Neuropsychopharmacology       Date:  1999-05       Impact factor: 7.853

5.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

Authors:  T Fukuda; I Yamamoto; Y Nishida; Q Zhou; M Ohno; K Takada; J Azuma
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

6.  A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.

Authors:  J Kirchheiner; K Nickchen; J Sasse; M Bauer; I Roots; J Brockmöller
Journal:  Pharmacogenomics J       Date:  2006-05-09       Impact factor: 3.550

7.  Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

Authors:  Alice I Nichols; Kasia Lobello; Christine J Guico-Pabia; Jeff Paul; Sheldon H Preskorn
Journal:  J Clin Psychopharmacol       Date:  2009-08       Impact factor: 3.153

8.  Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

Authors:  E A Muth; J T Haskins; J A Moyer; G E Husbands; S T Nielsen; E B Sigg
Journal:  Biochem Pharmacol       Date:  1986-12-15       Impact factor: 5.858

9.  CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.

Authors:  Thomas Rau; Gerlinde Wohlleben; Henrike Wuttke; Norbert Thuerauf; Jens Lunkenheimer; Mario Lanczik; Thomas Eschenhagen
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

10.  Venlafaxine hyponatraemia: incidence, mechanism and management.

Authors:  Milton Roxanas; Emily Hibbert; Michael Field
Journal:  Aust N Z J Psychiatry       Date:  2007-05       Impact factor: 5.744
View more
  16 in total

1.  Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.

Authors:  Tore Haslemo; Erik Eliasson; Marin M Jukić; Magnus Ingelman-Sundberg; Espen Molden
Journal:  Br J Clin Pharmacol       Date:  2018-11-11       Impact factor: 4.335

Review 2.  The role of cytochromes P450 in the metabolism of selected antidepressants and anxiolytics under psychological stress.

Authors:  Nina Zemanova; Pavel Anzenbacher; Eva Anzenbacherova
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2022-04-12       Impact factor: 1.245

3.  Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.

Authors:  Thu-Lan T Luong; Chelsea N Powers; Brian J Reinhardt; Peter J Weina
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-06-14

4.  Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.

Authors:  L Karlsson; A-L Zackrisson; M Josefsson; B Carlsson; H Green; F C Kugelberg
Journal:  Pharmacogenomics J       Date:  2014-09-23       Impact factor: 3.550

5.  Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).

Authors:  Elizabeth J J Berm; Eelko Hak; Maarten Postma; Marjolein Boshuisen; Laura Breuning; Jacobus R B J Brouwers; Ton Dhondt; Paul A F Jansen; Rob M Kok; Jan G Maring; Rob van Marum; Hans Mulder; Richard C Oude Voshaar; Arne J Risselada; Harry Venema; Liesbeth Vleugel; Bob Wilffert
Journal:  Trials       Date:  2015-01-31       Impact factor: 2.279

6.  Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer.

Authors:  Sofia Garcia; Michael Schuh; Anvir Cheema; Herjot Atwal; Paldeep S Atwal
Journal:  Case Rep Genet       Date:  2017-10-16

7.  Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress.

Authors:  Dragos Paul Mihai; Anca Ungurianu; Cosmin I Ciotu; Michael J M Fischer; Octavian Tudorel Olaru; George Mihai Nitulescu; Corina Andrei; Cristina Elena Zbarcea; Anca Zanfirescu; Oana Cristina Seremet; Cornel Chirita; Simona Negres
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

Review 8.  The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?

Authors:  Aizati N A Daud; Jorieke E H Bergman; Wilhelmina S Kerstjens-Frederikse; Henk Groen; Bob Wilffert
Journal:  Int J Mol Sci       Date:  2016-08-13       Impact factor: 5.923

9.  Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).

Authors:  Célia Lloret-Linares; Youssef Daali; Sylvie Chevret; Isabelle Nieto; Fanny Molière; Philippe Courtet; Florence Galtier; Raphaëlle-Marie Richieri; Sophie Morange; Pierre-Michel Llorca; Wissam El-Hage; Thomas Desmidt; Frédéric Haesebaert; Philippe Vignaud; Jerôme Holtzmann; Jean-Luc Cracowski; Marion Leboyer; Antoine Yrondi; Fabienne Calvas; Liova Yon; Philippe Le Corvoisier; Olivier Doumy; Kyle Heron; Damien Montange; Siamak Davani; Julien Déglon; Marie Besson; Jules Desmeules; Emmanuel Haffen; Frank Bellivier
Journal:  BMC Pharmacol Toxicol       Date:  2017-11-07       Impact factor: 2.483

10.  Cushing's Syndrome and Treatment-Resistant Depression.

Authors:  Lekhansh Shukla
Journal:  Indian J Psychol Med       Date:  2017 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.